(08-19-2019, 09:22 AM)DividendGarden Wrote:My thoughts are this is not a slam dunk. #2 is my biggest concern. Replacing a blockbuster drug is not automatic and that is why #3 occurred. ABBV inherited their aristocrat status from ABT so their inclusion i the club is meaningless to me. The political pharma hate-fest is just getting started with election coming.(08-17-2019, 05:23 PM)vbin Wrote: A bunch of folks here including me have bought ABBV recently. I have been giving it a good thought and would like to hear what folks think about 3 issues I see
1. Their debt
2. 50% of sales coming from Humira whose parents will expire soon.
3. Recent purchase of AGN
I'm curious on people's thoughts about ABBV, also.
Personally I want a position but not convinced it couldn't go lower. I want to enter as cheap as possible. I am selling puts and so far they expire worthless. I'll collect the premiums and keep doing it until I am forced in as low as possible. Just in case it turns out like PFE. I rode that dead horse for 15+ years waiting for a recovery. IMO ABBV is not a no brainer all will be surely well in a couple years proposition, though that is how DGI folks seem to regard it.
So I'm cautiously optimist or I wouldn't be trying to enter yet. I was amazed folks were interested a year ago. It seemed obvious to me it was a gamble. It looked like a yield trap to me. It looks better from here.